[go: up one dir, main page]

WO2006046994A3 - Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer - Google Patents

Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer Download PDF

Info

Publication number
WO2006046994A3
WO2006046994A3 PCT/US2005/027578 US2005027578W WO2006046994A3 WO 2006046994 A3 WO2006046994 A3 WO 2006046994A3 US 2005027578 W US2005027578 W US 2005027578W WO 2006046994 A3 WO2006046994 A3 WO 2006046994A3
Authority
WO
WIPO (PCT)
Prior art keywords
klf6
germline
cancer risk
alternative splice
polymorphism associated
Prior art date
Application number
PCT/US2005/027578
Other languages
English (en)
Other versions
WO2006046994A2 (fr
Inventor
John Martignetti
Goutham Narla
Scott Friedman
Original Assignee
Sinai School Medicine
John Martignetti
Goutham Narla
Scott Friedman
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sinai School Medicine, John Martignetti, Goutham Narla, Scott Friedman filed Critical Sinai School Medicine
Priority to US11/572,645 priority Critical patent/US20090325150A1/en
Priority to CA002579034A priority patent/CA2579034A1/fr
Priority to EP05807840A priority patent/EP1794322A4/fr
Publication of WO2006046994A2 publication Critical patent/WO2006046994A2/fr
Publication of WO2006046994A3 publication Critical patent/WO2006046994A3/fr
Priority to US13/529,974 priority patent/US20130035243A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/33—Alteration of splicing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes d'identification et de diagnostic de certains types de cancers et de leurs phases préliminaires chez un patient consistant à identifier des isoformes épissées de manière alternative de KLF6 de type sauvage (KLFwt), en particulier n'importe laquelle des isoformes sélectionnées dans le groupe contenant: variant-1 d'épissure de KLF6 (KLF6SV1), variant-2 d'épissure de KLF6 (KLF6SV2), et variant-3 d'épissure de KLF6 (KLF6SV3). L'invention concerne également des méthodes de diagnostic du cancer utilisant les polypeptides et les polynucléotides identifiés ici, de même que des méthodes de traitement de certains types de cancers par inhibition des polynucléotides et des polypeptides identifiés ici.
PCT/US2005/027578 2004-07-30 2005-08-01 Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer WO2006046994A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US11/572,645 US20090325150A1 (en) 2004-07-30 2005-08-01 Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk
CA002579034A CA2579034A1 (fr) 2004-07-30 2005-08-01 Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer
EP05807840A EP1794322A4 (fr) 2004-07-30 2005-08-01 Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer
US13/529,974 US20130035243A1 (en) 2004-07-30 2012-06-21 Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59278204P 2004-07-30 2004-07-30
US60/592,782 2004-07-30
US60130404P 2004-08-13 2004-08-13
US60/601,304 2004-08-13

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US13/529,974 Continuation US20130035243A1 (en) 2004-07-30 2012-06-21 Klf6 alternative splice forms and a germline klf6 dna polymorphism associated with increased cancer risk

Publications (2)

Publication Number Publication Date
WO2006046994A2 WO2006046994A2 (fr) 2006-05-04
WO2006046994A3 true WO2006046994A3 (fr) 2009-04-09

Family

ID=36228194

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/027578 WO2006046994A2 (fr) 2004-07-30 2005-08-01 Formes alternatives d'epissure de klf6 et polymorphisme d'adn de klf6 de cellules germinales associes a un risque accru de cancer

Country Status (4)

Country Link
US (2) US20090325150A1 (fr)
EP (1) EP1794322A4 (fr)
CA (1) CA2579034A1 (fr)
WO (1) WO2006046994A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2619732C (fr) 2005-09-12 2012-06-12 Phenomenome Discoveries Inc. Methodes permettant de diagnostiquer les etats pathologiques dus au cancer colorectal et au cancer de l'ovaire
US20080255764A1 (en) * 2005-09-12 2008-10-16 Phenomenome Discoveries Inc. Methods for the Diagnosis of Colorectal Cancer and Ovarian Cancer by the Measurement of Vitamin E-Related Metabolites
WO2008092280A1 (fr) * 2007-02-01 2008-08-07 Phenomenome Discoveries Inc. Procédés de diagnostic d'états de santé associés au cancer des ovaires, et de risque de tels états

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
CA2103064A1 (fr) 1991-05-14 1992-11-15 George Y. Wu Administration ciblee de genes codant pour des proteines immunogenes
ATE195656T1 (de) 1991-06-05 2000-09-15 Univ Connecticut Zielgerichtete freisetzung von genen, die sekretorische proteine kodieren
WO1993014188A1 (fr) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Virus cible
US5554601A (en) 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5635493A (en) 1993-12-01 1997-06-03 Marine Polymer Technologies, Inc. Methods and compositions for poly-β-1-4-N-acetylglucosamine chemotherapeutics
CA2220530A1 (fr) 1995-06-02 1996-12-05 Incyte Pharmaceuticals, Inc. Procede ameliore pour obtenir des sequences d'adn complementaire longues
EP1332362A4 (fr) * 2000-08-09 2006-07-05 Sinai School Medicine Facteur 6 du genre kruppel (klf6), proteine supprimant les tumeurs et diagnostics, therapies et criblages bases sur cette proteine
US20050181374A1 (en) * 2004-01-05 2005-08-18 Mount Sinai School Of Medicine Of New York University Kruppel-like factor 6 ( KLF6), a tumor suppressor protein, and diagnostics, therapeutics, and screening based on this protein

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6500938B1 (en) * 1998-01-30 2002-12-31 Incyte Genomics, Inc. Composition for the detection of signaling pathway gene expression

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1794322A4 *

Also Published As

Publication number Publication date
EP1794322A2 (fr) 2007-06-13
EP1794322A4 (fr) 2009-10-28
US20130035243A1 (en) 2013-02-07
WO2006046994A2 (fr) 2006-05-04
US20090325150A1 (en) 2009-12-31
CA2579034A1 (fr) 2006-05-04

Similar Documents

Publication Publication Date Title
WO2008061213A3 (fr) Variations génétiques associées à des tumeurs
IL177346A0 (en) Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
WO2008039974A3 (fr) Vaccins contre le cancer et méthodes de vaccination
WO2009062051A3 (fr) Procédés et compositions pour thérapie par anticorps
WO2010045318A3 (fr) Cibles géniques et protéiques exprimées par des gènes représentant des profils de biomarqueurs et des jeux de signatures par type de tumeurs
WO2002080754A3 (fr) Methodes d'utilisation d'une annexine permettant de visualiser la mort cellulaire in vivo et de traiter des etats pathologiques
EP2505668A3 (fr) Procédés à base de micro ARN pour le diagnostic d'un cancer du colon, du poumon, et du pancreas
WO2003050243A3 (fr) Nouveaux genes, nouvelles compositions, nouveaux kits et nouveaux procedes d'identification, d'evaluation, de prevention et de therapie du cancer du colon
WO2005023824A3 (fr) Procedes d'inhibition de la proliferation de cellules tumorales
WO2008011519A3 (fr) Inhibiteurs d'amigo-2 pour le traitement, le diagnostic ou la détection du cancer
WO2004060302A3 (fr) Methodes et compositions pour le diagnostic, le pronostic, et le traitement du cancer
WO2009014612A3 (fr) Nucléotides modifiés, procédés pour les préparer et les utiliser
WO2008061020A3 (fr) Méthodes permettant de traiter, de diagnostiquer ou de détecter un cancer
IL200120A0 (en) Compositions, reagents and kits for and methods of diagnosing, monitoring and treating obesity and/or diabetes
PL1668152T3 (pl) Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka
WO2010030171A8 (fr) Procédé pour le développement de marqueurs diagnostiques
WO2006009765A3 (fr) Procedes d'identification et d'utilisation de composes adaptes au traitement de cellules cancereuses resistantes aux medicaments
WO2004047623A3 (fr) Procedes pour identifier les risques de cancer du sein et traitements correspondants
WO2007023191A3 (fr) Marqueurs polypeptidiques pour le diagnostic du cancer de la vessie
WO2009085196A8 (fr) Procédés et compositions pour corréler des marqueurs génétiques avec un risque de cancer de la prostate
WO2006010150A3 (fr) Gènes domestiques et méthodes d'identification desdits gènes
WO2008070325A3 (fr) Variations génétiques associées à des tumeurs
WO2005014846A3 (fr) Procedes pour reperer le risque de cancer du sein et traitements correspondants
WO2009032172A3 (fr) Compositions de platine en tant que traitement pour des cancers liés à un transporteur de cations organiques
WO2005033133A3 (fr) Polynucleotides codant pour des nouveaux polypeptides erbb-2; trousses et methodes d'utilisation

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BW BY BZ CA CH CN CO CR CU CZ DK DM DZ EC EE EG ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KM KR KZ LC LK LR LS LT LU LV MA MG MK MN MW MX MZ NA NG NI NZ OM PG PH PL PT RO RU SC SD SE SK SL SM SY TJ TM TN TR TT TZ UA US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SZ TZ UG ZM ZW AM AZ BY KG MD RU TJ TM AT BE BG CH CY DE DK EE ES FI FR GB GR HU IE IS IT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2579034

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2005807840

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2005807840

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 11572645

Country of ref document: US